Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs ...
January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.
Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 ...
US pharma major Eli Lilly today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial ...
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
24/7 Wall St. on MSN14d
I Was Convinced Biotech Stocks Were Too Risky—This Innovation’s Changing the GameThe biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough ...
The Motley Fool on MSN15d
This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in ...
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
In fact, it’s starting already. Ahead of JP Morgan’s biotech jamboree this month in San Francisco, Johnson & Johnson (J&J), ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback